Skip to main content


03-04-2020 | Exenatide | News

Short-acting exenatide makes little difference to glycemia in type 1 diabetes

Short-acting exenatide “does not seem to have a future” as a standard adjunct treatment in people with type 1 diabetes, say the MAG1C investigators.

08-19-2019 | GLP-1 agonists | Highlight | News

Meta-analysis demonstrates cardioprotective effect of GLP-1 receptor agonists

Treatment with glucagon-like peptide receptor agonists reduces the risk for major adverse cardiovascular events among people with type 2 diabetes, indicate findings from a large meta-analysis.

12-08-2017 | Cardiovascular outcomes | News

Meta-analysis may support cardioprotective class effect for GLP-1 receptor agonists

A meta-analysis published in The Lancet Diabetes & Endocrinology is suggestive of a class cardioprotective effect for the glucagon-like peptide-1 receptor agonists.

09-15-2017 | Exenatide | EASD 2017 | News

EXSCEL: Near miss for exenatide cardioprotection

The results of the Exenatide Study of Cardiovascular Event Lowering study show that the glucagon-like peptide-1 receptor agonist has a neutral cardiovascular effect, the investigators have reported at the EASD annual meeting, in Lisbon, Portugal.

09-13-2017 | GLP-1 agonists | EASD 2017 | News

Incretins research update

One of the first original research sessions of EASD 2017 included updates from the TECOS, SUSTAIN 6, and DURATION-7 and -8 trials.

09-13-2017 | Exenatide | EASD 2017 | News

DURATION-8: Exenatide efficacy durable to 1 year

The 52-week findings of the DURATION-8 trial show durable glycemic control with the combination of exenatide and dapagliflozin in patients with type 2 diabetes.

06-12-2017 | Medications | ADA 2017 | News

Research round-up: medications for type 2 diabetes

One of the final sessions on Saturday featured the presentation of new, and mostly positive, data on medications for glycemic control in patients with type 2 diabetes.

09-19-2016 | Type 2 diabetes | News | Article

DURATION-8 combines antidiabetic medications to promising effect

Combining a glucagon-like peptide-1 receptor agonist with a sodium-glucose co-transporter-2 inhibitor improves glycaemic control more than either therapy alone in patients with Type 2 diabetes, shows the DURATION-8 trial.

Related topics



Image Credits